Later in 2018 the United Nations Commission on Narcotic Drugs, will vote on whether or not to recategorize the recently popularized cannabidnoid Cannabidiol (CBD), found in numerous products throughout the world.
CBD is one of the many cannabinoids that can be extracted from the industrial hemp and cannabis plants. The World Health Organization just recently released a scientific research report conducted on found CBD to be non-psychoactive, non-addictive, and also noted that it has potential health benefits, more specifically to calm seizures connected with epilepsy.
Now the United Nations Commission on Narcotic Drugs Control and the United States Federal Government are requesting that citizens from the around the world send in their thoughts and comments regarding their comments and experiences with Cannabidiol (CBD).
The deadline to send in your comments is February 26, 2018. Visit the link below.
Why is this important for investors?
As of right now there are hundreds of companies around the world manufacturing and selling CBD based products. Whether it be in the form of tinctures, topicals, capsules, sprays, gummy bears or bath bombs they are selling because the end result is effective for consumers of the finished product.
Projections about the CBD industry are exponentially growing into multiple billions of dollars. The more legislation opens up around the world, the most the more private and public companies in the CBD sector with flourish.
Companies to keep an eye on:
GW Pharmaceuticals GWPH (NASDAQ)
Marijuana Company of America MCOA (OTC)
Global Hemp Group GHG (CSE) GBHPF (OTC)
Aurora Cannabis ACB (TSE)
Canopy Growth WEED (TSE)
Insys Therapeutics Inc- INSY (NASDAQ)
Medical Marijuana, Inc. MJNA (OTC)